department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Neuren Pharmaceuticals Ltd · pharmadog

PUBLIC COMPANY

Neuren Pharmaceuticals Ltd

updated 1mo ago

community read0 votes

pipeline

1

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 3

Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Neuren Pharmaceuticals Ltd jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase3A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndromerecruitingn=160
phase3An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndromenot yet recruitingn=180
phase2An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)completedn=28
phase2An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)completedn=18
phase2An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndromecompletedn=17
phase2An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)withdrawn